The study, conducted in mice, is the first to show that creatine uptake is critical to the anti-tumor activities of what is known as killer T cells, the foot soldiers of the immune system.
In most people with chronic myelogenous leukemia, cancerous stem cells remain in the body for years after remission, and the cancer can recur.
When reviewers were subspeciality-trained, misclassification rates were the lowest.
The finding suggests that predicting how a person’s cancer will evolve may lie in their inherited genetic material.
The approach could eventually be useful not only for treating cancer, but also for lipid metabolism-related conditions like diabetes.
The researchers’ goal was to create a therapy that would permanently boost the body’s ability to naturally produce more iNKT cells.
Innovative technology improves visualization of a patient’s anatomy.
The study results have the potential to establish a new standard for using this method to actively monitor prostate cancer.
The prominent cancer researcher is honored for his invention of the breast cancer drug Herceptin.
The invention relies in part on another UCLA invention, photonic time stretch.
Of mice that received high doses of radiation, nearly all that received a compound developed by UCLA scientists survived.
Research brief: UCLA researchers developed a drug delivery system that can break through the blood-brain barrier.
The system could help reduce errors in differentiating ductal carcinoma in situ, a noninvasive type of cancer, from breast atypia.
The observation helps explain why, as people age, the prostate tends to grow, leading to an increased risk for cancer and other conditions.
Research brief: The study recommends that the new procedure should become the standard of care.
The researchers' study builds on their discovery last year of a gene called mEAK-7, which is important for cell proliferation and migration.
The discoveries by an interdisciplinary team of UCLA scientists could improve the diagnoses of these aggressive cancers.
Research Brief: An increase in the state's HPV vaccination rate would reduce the number of preventable cancers and the financial burden that treatment for these cases would create, the study found.
50% of treatments could have been avoided using the new tool, a UCLA-led study finds.
Q&A with the newly appointed director of cancer population genetics at UCLA’s Jonsson Comprehensive Cancer Center.
Combining biopsy strategies allowed doctors to find up to 33% more cancers.
The approach shows promise for extending the lives of people with a type of melanoma that contains a potent gene mutation, BRAF V600E.
“This trial was unique because it looks at younger women who haven’t gone through menopause,” said Dr. Sara Hurvitz, the study’s lead author.
“We can no longer look at this disease as one in which we should always be measuring survival in months,” said UCLA’s Dr. Edward Garon, the lead author.
The findings will both help identify women who are at highest risk of developing ovarian cancer and pave the way for identifying new therapies that can target these specific genes.